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sponse pattern was obtained. There was no decremental conduction over
the retrograde FPwith V stimulation.
Conclusions: 1) The reentrant circuit of AVNRT can be reset from multiple
sites. 2} The circuit as a whole demonstrates partial excitability with hetero-
genicityof conduction over individual pathways. 3) A difference in the mea-
sured excitable gap of >20 msec dependent on stimulation site was seen in
5/8 patients and suggests a functionally determined circuit and anisotropic
reentry.
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1725-1 I Long-term Impact of a Patent Infarct-related Artery:
1-Year Survival In the GUSTO Trial
Joseph A. Puma, Michael H. Sketch. Jr., R. John Simes, Douglas C. Morris. Eric
J. Topol, Robert M. Califf, GUSTO Investigators. Duke University Medical Center,
Durham, N.C.
The "open-artery" hypothesis has been validated in the acute phase of coro-
nary occlusion. Controversy remains regarding long-term survival and the
need for revascularization. To examine the long-term impact of a patent
infarct-related artery in the GUSTO trial, we evaluated prospectively collected
data on 41,021 patients treated with thrombolytic therapy for acute infarc-
tion. Patency data were available in 12,864 patients undergoing their first
post-infarction angiogram who had no prior history of PTCA or CABG and
who were not enrolled in the angiographic substudy. The infarct-related artery
was open in 8,810 and closed in 4,054 patients. In the open artery cohort,
50% were treated medically, 38% with PTCA, and 12% with CABG. The cor-
responding percentages in the closed artery cohort were 45, 41 and 14, re-
spectively.
Baseline demographics, risk factor profiles, extent of disease and time to
treatment were similar for both groups. Patients with a closed artery had a
slightly higher incidence of Killip Class III and IV than the open artery cohort
(2% vs 1%). As expected, patients treated medically and with PTCA in both
groups had a preponderance of 1 and 2 vessel disease and patients treated
with CABG had a preponderance of 2 and 3 vessel disease.
1-Year Mortality Open Artery Closed Artery P-value
- Medical Therapy (%) 33 8.5 <0001
-PTCA(%I 2.5 88 <0.001
-CABG(%I 4.2 9.6 <0.001
Conclusion: Infarct-related artery patency confers a survival advantage at
1-year across all thrombolytic treatment strategies in patients with acute my-
ocardial infarction.
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Long Term Outcome After Early Prehospltal Initiated
Thrombolysis
Marc A. Brouwer, Jenny S. Martin, Mark J. Wirkus, Charles C. Maynard, Paul
E. Litwin, Freek W.A. Verheugt, W. Douglas Weaver, MITI Pre-Hospital Study
Investigators. University of Washington, Seattle. WA
In order to determine the long-term effects of very early thrombolytic treat-
ment on outcome after myocardial infarction. patients (pts) in the MITI pre-
hospital thrombolysis trial were assessed for cardiac events (death. admis-
sion for angina, myocardial infarction. congestive heart failure, revascular-
ization) during a mean period of 33 months follow-up. Outcome in 175 pre-
hospital treated pts (PH-group) was compared to 185 pts allocated to treat-
ment after hospital arrival (H-group). The median time from symptom onset
to treatment for the PH-group was 77 min. (56, 101; 25. 75th percentile). and
forthe H-groupwas 110 min. (85,140). Survival at two years was 89% forthe
PH-group and 91 % forthe H-group (p = 0.46). Event free survival at two years
was 51% and 60%, respectively Ip ~ 0.69). The event rate (# events/100
treated pts!follow-up year) was 34.2 in the PH-group and 41 .0 for the H-group
(p = 0.28).
Pts treated within 70 min. after symptom onset (n = 82) had improved sur-
vival at the time of discharge. 98.8% vs. 91.3%, but in a multi-variate analysis.
subsequent mortality after discharge was related to older age. a history of
heart failure, or prior bypass surgery but not initial time to treatment.
Conclusion: In the MITI prehospital trial, the short and long-term outcome
for pts receiving pre-hospital and hospital initiated thrombolyses is similar.
Time to treatment is an important predictor of hospital mortality but does not
affect the likelihood of survival in the years afterdischarge.
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Extent of Early ST Segment Elevation Resolution: Not
Only a Strong Predictor of Outcome in Patients with
Acute Myocardial Infarction but Also a Sensitive
Measure to Prove the Superiority of a Thrombolytic
Agent?
Rolf Schroder, Karl Wegscheider. INJECT TRIAL Group. Free University Berlin.
Germany
Data from small prospective studies and a retrospective analysis of 1516 pa-
tients of the ISAM study showed that applying two cutoff points with ST el-
evation resolution of 1) ~70%, 2) <70-30%, 3) <30->0% 3 hours after start
of thrombolysis is most efficient to predict infarct size, left ventricular func-
tion, and survival with follow up 6 years regardless of whether patients have
had streptokinase or placebo treatment. A beneficial effect of thrombolytic
therapy was related to a larger proportion of patients with ~70% ST resolu-
tion and less <30% ST resolution (p = 0.0000). In multivariate analysis. ST
resolution <30% was the most powerful independent predictor of early mor-
tality (JACC 1994; 24: 384). In an ECG substudy on all German patients of
the INJECT TRIAL (Multicentre study aimed to compare the efficiency of 1.5
MU Streptokinase with 2 x 10 MU r-PA [Reteplase]bolus injection in 6000
patients). the prognostic power of these ECG markers shall be assessed
prospectively in all patients and in the two treatment groups. From an overall
interim analysis (still blinded to treatment group) on 1118 patients, number
of patients II and percentages of deaths at 3 month follow up for the three
groups of ST elevation resolution are shown in the table:
Anterior MI INa = 531)
5T Resolution :>:70% (165) <70-30% (198) <30% (1681
Mortality 4.2% 17) 5.6%(11} 17.3% (29)
Inferior MI (No = 587)
5T Resolution :>:70% (355) <70-30% (120) <30% (112)
Mortality 3.1%(11) 7.5%(9) 14.3%(16)
Final data on about 2000 patients including significance of differences be-
tween the two thrombolytic agents will be presented at the meeting.
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Late Survival Following Early Coronary Intervention
After Fibrinolytic Therapy with Streptokinase in Acute
Myocardial Infarction (Results of a randomized trial:
SIAM-I)
Bernd Hammer. Cern Ozbek, Armin Heisel, Wolfgang Bay, Gunther Berg.
Benno Hennen, Klaus-Dieter Heib, Markus Hohn, Hauke Tager. Hermann Schieffer,
SIAM Study Group. Medizinische Universittitsklinik Homburg/Saar, Germany
324 pts with acute myocardial infarction were treated with intravenous Strep-
tokinase «4 hrs after onset of symptoms. 1.500.000 U/1 hr) in 13 acute care
hospitals and were centrally randomized by phone call to the university hos-
pital in two groups during fibrinolysis.
Group A: (invasive strategy) CA with PTCA/CABS 14 to 48 hours after start
of treatment and predischarge control CA.
Group B: Icontrol group) no CA within the first 21 days, unless there is evi-
dence for ischemia and predischarge control CA.
In Gr-A 14/158 (=9%) pts. in Gr-B 10/166 (=6%) pts died before hospi-
tal discharge (n.s.). In a follow-up period of at least 24 months (Median 35
months) 13/1441=9%) pts of Gr-A and 14/156 (=9%) pts of Gr-B died (n.s.).
All other patients (n = 273; Gr-A: 131, Gr-B: 142) were followed for a me-
dian time of 76 months (30 - 89 months. 1723 patient years). In Gr-A 20/131
(= 15%) pts and in Gr-B 7/142 (=5%) pts died during this period (p < 0.008).
Cumulative number of deaths in Gr-A and Gr-B
Time Gr-A Gr-B p-value
<14 hrs 3(~2%1 3(~2%) n.s.
14--48 hrs 9(=6%) 8(=5%) n.s.
in-hospital 14(~9%) 10(~6%) n.s.
3-year-FU 27 (~17%) 24(~14%) n,s.
6-year-FU 47 (=30%) 31 (~19%) <0.03
Conclusion: This data exclude even a long-term superiority of an invasive
approach to patients with fibrinolytic treated acute myocardial infarction. A
detailed stratification to identify patients who will benefit from coronary inter-
vention is needed.
